Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition
Science Advances · 2026
DOI: 10.1126/sciadv.aeb4023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Hyerim Jung und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Pohang University of Science and Technology, Pohang, Gyeongbuk 37673, Korea. Hauptthemen laut MEDLINE: DNA Topoisomerases, Type I, Immunoconjugates, Cyclin-Dependent Kinases, Topoisomerase I Inhibitors. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Cancer Institute, Korea Basic Science Institute.
Abstract (Originalsprache)
This study investigates the transcriptional impact of Q901, a highly selective cyclin-dependent kinase 7 (CDK7) inhibitor in clinical development. Q901 primarily disrupted MYC and E2F-dependent transcription programs, down-regulating cell cycle control and DNA damage repair pathways. CDK7 binding at the promoter-proximal regions was markedly stabilized by Q901, leading to reduced occupancy of MYC, E2F, and RNA polymerase II (RNAPII). These findings offered a novel therapeutic strategy to enhance cancer susceptibility to topoisomerase I (TOP1) DNA-protein cross-links (TOP1-DPCs) induced by TOP1 inhibitors. Resistance to TOP1 inhibitors arises through activation of DNA repair pathways when elongating RNAPII encounters TOP1-DPCs. By suppressing RNAPII transition from initiation to elongation and DNA repair pathways, Q901 stabilizes TOP1-DPCs and sensitizes tumors to TOP1 inhibitors. Preclinical studies demonstrated enhanced tumor suppression when combining Q901 with TOP1 inhibitor–based antibody-drug conjugates (TOP1i-ADCs), highlighting its potential as a therapeutic option for cancers resistant to TOP1i-ADC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, Pohang University of Science and Technology, Pohang, Gyeongbuk 37673, Korea.
- Qurient Co. Ltd., C801, 242 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13487, Korea.
- University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
ORCID-Profile: Hyerim Jung, Yoonji Lee, Yeejin Jeon, Dahun Um, Mooyoung Seo, Dongsik Park, Seung-Joo Lee, Jaeseung Kim, Yilun Sun, Anish Thomas, Kiyean Nam, Tae-Kyung Kim
Förderung
- Intramural NIH HHS
- National Cancer Institute
- Korea Basic Science Institute
- National Research Foundation of Korea
- Samsung Science & Technology Foundation
- Multitasking Macrophage Research Center
Zitieren
APA
Jung, H., Lee, Y., Yu, D., Jeon, Y., Kang, H., Um, D., Seo, M., Park, D., Kim, J., Lee, S. J., Kim, J., Escobedo, L., Sun, Y., Thomas, A., Nam, K., & Kim, T. K. (2026). Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition. Science Advances. https://doi.org/10.1126/sciadv.aeb4023
Vancouver
Jung H, Lee Y, Yu D, Jeon Y, Kang H, Um D, et al. Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition. Science Advances. 2026. doi:10.1126/sciadv.aeb4023
BibTeX
@article{Jung2026,
author = {Jung, Hyerim and Lee, Yoonji and Yu, Donghoon and Jeon, Yeejin and Kang, Hwankyu and Um, Dahun and Seo, Mooyoung and Park, Dongsik and Kim, Jeongjun and Lee, Seung-Joo and Kim, Jaeseung and Escobedo, Lauren and Sun, Yilun and Thomas, Anish and Nam, Kiyean and Kim, Tae-Kyung},
title = {Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeb4023}
}
EUVIMED